Physician profile
Gregory Browning
NPI 1538175245
$4,708.33
in general payments reported to CMS, 2019-2025
28 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $627 · 2021: $1,212 · 2022: $1,217 · 2023: $929 · 2024: $183 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,233.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $1,155.09 | 2019-2023 | Prolate, Nalocet |
| Novo Nordisk INC | $713.27 | 2019-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $432.89 | 2021-2023 | Relistor |
| Scilex Pharmaceuticals INC. | $291.67 | 2022-2023 | Ztlido |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.87 | 2021-2024 | Ofev |
| Biodelivery Sciences International, INC. | $227.30 | 2019-2021 | |
| Abbvie INC. | $220.90 | 2020-2023 | Creon, Linzess |
| Collegium Pharmaceutical, INC. | $203.59 | 2021-2023 | Belbuca, Xtampza |
| Glaxosmithkline, LLC. | $172.05 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Virtus Pharmaceuticals LLC | $167.02 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $162.04 | 2022 | |
| Alkermes, INC. | $156.17 | 2019-2021 | |
| Pfizer INC. | $102.05 | 2019-2021 | |
| Urovant Sciences INC | $89.76 | 2022 | |
| Zyla Life Sciences, INC. | $65.34 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $57.97 | 2020-2021 | |
| Kaleo, INC. | $56.11 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $34.88 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.95 | 2021 | |
| Azurity Pharmaceuticals, INC. | $19.84 | 2023 | Horizant |
| Nevro Corp. | $17.93 | 2023 | Senza |
| Abbott Laboratories | $17.24 | 2023 | Freestyle Libre 3 |
| Grt US Holding, INC. | $17.02 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.91 | 2019 | |
| Shire North American Group INC | $15.80 | 2019 | |
| Indivior INC. | $14.42 | 2019 | |
| Horizon Therapeutics Plc | $12.69 | 2019 | |
| Lilly USA, LLC | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Browning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.